Endometrial cancer. Multiple solid tumor types. Early Reversal of pharmacologically-induced mydriasis, i. Late Q1 Delaying aging and prolonging healthy lifespan. Initial data from phase I study of FHD Synovial sarcoma. Interim data readouts phase II trial of Vidutolimod in combination with Keytruda. Rest assured that we will keep you informed as soon as any information is released in the upcoming months.
Please see the press release that provides further details about this exciting development. Targeting beta-catenin in this way may hold promise for desmoid sufferers, as the science that has evolved shows that desmoid tumors are due to mutations in the beta-catenin gene, CTNNB1, which cause improper degradation of beta-catenin. We will keep you posted as more details are finalized for this trial.
Until then, we recommend watching the video of Dr. Search for: Search. Shopping Bag. To view all clinical trials in desmoid tumors, visit here. Researchers Search the database to stay up to date on developments in your field, find collaborators, and identify unmet needs. Study Record Managers Learn about registering studies and about submitting their results after study completion. National Library of Medicine U.
National Institutes of Health U. Department of Health and Human Services. On Target Laboratories, Inc. Abivax SA announced that the European Medicines Agency provided their feedback in the context of the scientific advice meeting that supports advancing ABX into phase 3 clinical testing for the treatment of ulcerative colitis and subsequent potential marketing authorization submission and commercialization.
Oncopeptides AB announces that the data from the randomized head-to-head phase 3 OCEAN study, evaluating the efficacy and safety of melflufen plus dexamethasone versus pomalidomide plus dexamethasone in lenalidomide refractory patients with relapsed refractory multiple myeloma that have received prior lines of therapy, have been published in the Lancet Hematology.
Arrowhead Pharmaceuticals Inc.
0コメント